慢性肾脏病驱动免疫衰老:机制与潜在干预
综述指出慢性肾脏病通过尿毒症毒素蓄积、氧化应激和免疫信号失调加速固有与适应性免疫细胞早衰,导致免疫激活失调和监视功能受损,进而加重肾损伤及合并症风险。透析可能因氧化与抗原应激加速免疫衰老,肾移植可部分逆转,而mTOR抑制剂、senotherapeutics、SGLT2抑制剂等具潜在干预作用。
要点
- CKD通过尿毒症毒素、氧化应激和免疫信号失调驱动免疫细胞早衰。
- 透析可能加速免疫衰老,肾移植可部分逆转CKD诱导的免疫衰老。
- senotherapeutics、SGLT2抑制剂等策略有潜力延缓CKD相关免疫衰老。
核心结论
- CKD加速免疫衰老并形成恶性循环,加重肾损伤和合并症风险。
- 多种靶向免疫衰老的治疗策略正在涌现,具延缓早衰潜力。
研究设计与样本
- 本文为综述,系统概述CKD与免疫衰老的机制联系及新兴治疗策略。
主要发现
- CKD通过尿毒症毒素蓄积、氧化应激和免疫信号失调促进全身炎症和免疫细胞早衰。
- 透析虽清除尿毒症毒素,但可能通过氧化和抗原应激诱导端粒缩短和T细胞耗竭,加速免疫衰老。
- 肾移植可部分逆转CKD诱导的免疫衰老,但常用免疫抑制剂可能通过损害胸腺功能、耗竭初始T细胞和抑制NK细胞活性进一步促进免疫衰老。
- mTOR抑制剂通过促进自噬和抑制促炎通路显示抗衰老效应。
临床怎么用
- 肾内科医生应认识CKD加速免疫衰老及其对合并症的影响。
- 评估透析和免疫抑制方案对免疫衰老的潜在加速作用。
- 关注senotherapeutics、SGLT2抑制剂等靶向免疫衰老策略的潜在应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunosenescence, a state marked by immune dysfunction, chronic low-grade inflammation, and impaired pathogen defense, is accelerated in CKD. CKD promotes systemic inflammation through the accumulation of uremic toxins, oxidative stress, and dysregulated immune signaling, all driving premature aging of both innate and adaptive immune cells. These mechanisms result in dysregulated immune activation and impaired surveillance, thereby aggravating kidney damage and increasing the risk for comorbidities. Despite removing uremic toxins, dialysis may further accelerate immunosenescence by exposing immune cells to oxidative and antigenic stress, inducing telomere shortening and T-cell exhaustion. Kidney transplantation can partially reverse CKD-induced immunosenescence by restoring kidney function. Commonly used immunosuppressive agents, however, may further promote immunosenescence by impairing thymic function, depleting naïve T cells, and suppressing natural killer cell activity. However, mammalian target of rapamycin (mTOR) inhibitors have shown anti-aging effects by promoting autophagy and inhibiting proinflammatory pathways. Therapeutic strategies targeting immunosenescence in CKD have been gaining momentum. Senotherapeutics can eliminate senescent cells and reduce senescence-associated secretory phenotype (SASP)-mediated inflammation. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, caloric restriction, microbiome modulation, mesenchymal stem cell therapies, and KRTs also offer the potential to slow accelerated immunosenescence as a consequence of CKD. Here, we provide a comprehensive overview of the mechanisms linking CKD and immunosenescence, along with emerging therapeutic strategies that have the potential to target premature aging.
引用
- Song Z, Tsou S, Martin F, et al. Kidney Disease as a Driver of Immunosenescence: Mechanisms and Potential Interventions. J Am Soc Nephrol. 2025. PMID: 40938671. doi:10.1681/ASN.0000000896
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。